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Anaplastic thyroid cancer (ATC) is a rare, ag-
gressive malignancy. It accounts for less than 5% of 
thyroid cancers, but over half of thyroid cancer-re-
lated mortalities [1–3]. Patients usually present with 
a rapidly enlarging neck mass and symptoms of 
invasion of nearby structures, including recurrent 
laryngeal nerve, larynx, trachea and oesophagus. 
Symptoms include dysphagia, hoarseness, stridor 
and dyspnoea [4]. More than 70% of patients have 
tumour infiltration of surrounding tissues, more 
than 75% have cervical nodal metastases and 50% 
have distant metastatic disease at presentation [1, 
4]. Most cases are inoperable at presentation due 
to invasion of carotid arteries, prevertebral fascia, 
AbstrAct
backround: The purpose of this study is to assess the impact of trimodal therapy [surgery, chemotherapy and external beam 
radiotherapy (eBrT)] in patients with anaplastic thyroid cancer (aTc) treated with curative intent. 
Materials and methods: retrospective review of patients with aTc treated at a tertiary referral centre between January 2009 
and June 2020. Data were collected regarding demographics, histology, staging, treatment and outcomes.
results: seven patients (4 female) were identified. Median age was 58 years (range 52–83 years). all patients received eBrT 
with concurrent doxorubicin. six patients received surgery followed by chemoradiotherapy (crT), and one underwent neo-
adjuvant crT followed by surgery. Median radiological tumour size was 50mm (range 40–90 mm). six patients had gross 
extrathyroidal extension and three had N1b disease. prescribed radiotherapy schedules were 46.4 Gy in 29 bidaily fractions 
(n = 2, treated 2010), 60 Gy in 30 daily fractions (n = 2), 66 Gy in 30 fractions (n = 2) and 70 Gy in 35 fractions (n = 1; patient 
received neoadjuvant crT). crT was discontinued early for two patients due to toxicities. at median follow up of 5.8 months, 
42.9% (3/7) patients were alive and disease-free. Only one patient developed a local failure. Three patients died from distant 
metastases without locoregional recurrence. 
conclusions: Despite poor prognosis of aTc, selected patients with operable tumours may achieve high locoregional control 
rates with trimodal therapy, with possibility of long-term survival in select cases.
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and superior mediastinum [5]. Prognosis is grave, 
with studies reporting one year survival of less than 
20% and a median survival of less than six months 
[6, 7]. Most deaths occur due to uncontrolled local 
disease [1].
Some studies have found aggressive treatment 
with trimodal therapy [surgery, chemotherapy and 
external beam radiotherapy (EBRT)] can improve 
outcomes, specifically locoregional recurrence free 
survival, which can improve patients’ quality of life 
given the local aggressiveness of ATC [6, 7]. 
Doxorubicin is the systemic agent most report-
ed in the literature and is given concurrently with 
EBRT [6–10]. This is the regimen used in our can-
cer centre.
The purpose of our study was to examine the 
outcomes for patients with a diagnosis of ATC who 
received trimodal therapy in our cancer centre and 
to compare these outcomes with the published lit-
erature. 
Materials and methods
The present study comprised a retrospective re-
view of patients undergoing trimodal therapy for 
ATC at our institution between January 2009 and 
June 2020. Ethical approval was granted by the in-
stitution’s clinical research ethics committee. All 
patients presenting to our institution with ATC are 
discussed at the multidisciplinary Head and Neck 
Cancer meeting. Patients are considered for prima-
ry surgical treatment in cases which are considered 
operable, usually based on no gross radiological 
encasement of carotid arteries, invasion of prever-
tebral muscle, direct invasion of superior mediasti-
num, or extensive aerodigestive tract invasion; and 
with no evidence of distant metastases. 
Adjuvant chemoradiotherapy (CRT) (with doxo-
rubicin 10–20 mg/m2 IV) was offered to patients 
with a good performance status and either stage 
IVA or IVB disease. Pre-operative imaging, op-
erative notes and pathological reports helped to 
define the treatment volumes. For adjuvant EBRT 
using three dimensional conformal radiation ther-
apy (3DCRT) and volumetric modulated radiation 
therapy (VMAT), the high dose volume included 
the surgical thyroid bed and involved nodal levels 
with an elective volume to cervical levels II–VI and 
superior mediastinum if not already included in the 
high dose region. 
Radiotherapy, histopathological, pharmacy and 
surgical databases of the treating institutions were 
searched for patients diagnosed with ATC during 
the study period. Data were collected regarding de-
mographics, histology, staging, treatment and out-
comes. Study endpoints were local recurrence, the 
development of metastatic disease and death from 
any cause. Median follow up was from the date of 
primary surgery to the last known clinical or radio-
logical review. Tumours were staged according to 
the TNM Classification of Malignant Tumours 8th 
edition [11]. Clinical notes, histopathology reports 
and clinical imaging were reviewed for each patient. 
Toxicity data was recorded according to the Nation-
al Cancer Institute Common Terminology Criteria 
for Adverse Events (CTCAE) grading system [12]. 
results
patients and tumour characteristics
25 patients with a diagnosis of ATC between 
January 2009 and June 2020 were identified. Of 
these, seven patients received trimodal therapy and 
formed our study population. The remaining pa-
tients were considered to have tumours which were 
inoperable or to be unfit for surgery.  
The tumour characteristics for included patients 
are summarised in Table 1. Median age at com-
mencement of treatment was 58 years (range 52–83 
years). Four patients were female, and three were 
male. Six patients had gross extrathyroidal exten-
sion and three had lateral neck metastases (N1b 
disease) at diagnosis. Local structures invaded at 
diagnosis included the infrahyoid muscles (n = 5), 
internal jugular vein (n = 4), constrictor muscles 
(n = 2), thyroid cartilage (n = 2), sternocleidomas-
toid muscle (n = 2), oesophagus (n = 1), prever-
tebral muscle (n = 1) and common carotid artery 
(n = 1).
No patient had distant metastases at diagnosis. 
The median radiological tumour size was 50 mm 
(range 40–90 mm) and pathological tumour size 
was 66 mm (range 43–110 mm). Two patients had 
coexistent differentiated thyroid carcinoma (pap-
illary-follicular variant and follicular). In both of 
these cases ATC was present as a major component. 
BRAF mutation testing was implemented in the 
treating institution in 2018 and the three patients 
who were diagnosed following this were BRAF mu-
tation negative. 
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Treatment characteristics
Treatment characteristics are summarised in Ta-
ble 2. Six patients were treated with surgery followed 
by adjuvant CRT. One patient received neoadjuvant 
CRT followed by surgery. This patient had tumour 
which was considered inoperable at initial presenta-
tion due to invasion of the right common carotid ar-
tery, but was rendered operable by CRT. All patients 
underwent total thyroidectomy, with five patients 
also undergoing lateral neck dissection. In all cases, 
complete macroscopic clearance of all tumour, thy-
roid tissue, and nodal disease was achieved. One 
patient’s recurrent laryngeal nerve was sacrificed 
during surgery in order to achieve gross total resec-
tion. No patient underwent tracheostomy. 
Once daily radiotherapy doses ranged from 
60 Gy to 70 Gy. The higher dose of 70 Gy was 
prescribed given the neo-adjuvant timing of ra-
diotherapy. The decision of whether to treat with 
60 Gy or 66 Gy for the remaining cases was made 
by the treating radiation oncologist. Doxorubicin 
doses were prescribed by the treating medical 
oncologist and ranged from 10 to 20 mg/m2. CRT 
was discontinued early for two patients due to 
toxicities including dysphagia, fatigue and radia-
tion dermatitis. Both patients required admission 
during their radiotherapy for management of the 
toxicities. Patient 1 received 52 Gy out of planned 
60 Gy. Patient 3 received 60 Gy out of planned 
66 Gy. 













1 T3aN0 40 43 Yes (papillary — follicular variant) No
2 T4bN1b 50 N/a No Yes
3 T4aN1b 50 72 No Yes
4 T4bN0 67 110 No Yes
5 T4bN0 90 100 Yes (follicular) Yes
6 T4aN0 45 55 No Yes
7 T4aN1b 49 60 No Yes









Doxorubicin dose  
[mg/m2] 
















Reason for early 
discontinuation 
of CRT




2 Neoadjuvant r0 10 (7; once weekly) 70/35 70/35 3DcrT N/a
3 adjuvant r0 10 (4; once weekly) 60/30 66/33 3DcrT
Dysphagia, 
fatigue
4 adjuvant r0 10 (7; once weekly 66/33 66/33 3DcrT N/a
5 adjuvant r1
15 (14; once weekly  
× 2 weeks for initial  
2 cycles, then once weekly 
× 3 weeks followed by  
1 week gap for remaining 
12 cycles)
60/30 60/30 3DcrT N/a
6 adjuvant r0 20 (13; once weekly) 46.4/29 bidaily 46/29 bidaily 2DrT N/a
7 adjuvant r0 10 (17; once weekly) 46.4/29 bidaily 46/29 bidaily 2DrT N/a
crT — chemoradiotherapy; r0 — microscopically margin-negative resection; r1 — microscopic margins positive for tumour; VMaT — volumetric modulated arc 
therapy; 3DcrT — 3D-conformal radiation therapy; 2DrT — conventional (2D) radiation therapy
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Outcomes
The outcomes for each patient following trimodal 
therapy are summarised in Table 3. Median follow 
up was 5.8 months (range 3.8–42.9 months) for all 
patients and 9.8 months (range 3.8–42.9 months) for 
surviving patients. At the time of writing, 42.9% (3/7) 
patients are alive and disease-free. One patient devel-
oped local recurrence and three developed distant 
metastases following treatment. These patients re-
ceived palliative care input for management of symp-
toms including pain and dyspnoea, and nutritional 
support. All four patients who developed disease re-
currence died. The patient who received neoadjuvant 
CRT had a complete pathological response at the time 
of surgery. This patient remains alive and disease-free 
at 9.8 months following surgical resection. 
Toxicities
Acute CRT toxicities are shown in Table 4.  Due to 
a short follow-up, late side effects were not recorded.
Discussion
In this study, we found the combination of sur-
gery and concurrent doxorubicin-based CRT to be 
highly effective in controlling local disease, with 6/7 
patients achieving local control. Given that most 
patients die from uncontrolled local disease with 
high rates of local recurrence, local control is para-
mount in maintaining quality of life. Moreover, 3/7 
patients had no recurrence of anaplastic carcinoma 
at the time of writing; however, the length of fol-
low-up for two of these is less than one year. These 
findings would support trimodal treatment for pa-
tients with ATC who are considered operable at 
presentation, or who are rendered operable by CRT. 
The two patients who received 46Gy in 29 bidai-
ly fractions were treated in 2010. This fractionation 
schedule is described in a paper by Tennvall et al. 
[8] which reports on three protocols combining 
doxorubicin, hyperfractionated radiotherapy and 
surgery. Bidaily fractionation regimens for ATC 
were reported on in several studies from 2002 to 
2009 as being well tolerated and associated with 
improved local control and median survival when 
given as part of multimodal treatment [6, 8, 10, 
13]. There was an institutional transition follow-
ing this to daily fractionation schedules, as has 
been the case in more recently published studies, 
















1 3 3 2 2 Yes Yes
2 2 2 2 0 No No
3 3 3 3 2 Yes Yes
4 2 2 2 3 No No
5 3 4 2 2 Yes No
6 1 1 1 1 No No
7 0 0 0 1 No No
cTcae — National cancer Institute common Terminology criteria for adverse events




Time from surgery to most recent review/ 
/progression of disease (months)
Time from surgery to death (months)
1 N/a 3.8 N/a
2 N/a 9.8 N/a
3 Local recurrence 5.3 9.3
4 pulmonary metastases 4.2 4.6
5 N/a 42.9 N/a
6 pulmonary metastases 6.6 9.1
7 pulmonary metastases 5.8 7.4
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with EBRT and improved outcomes with doses 
of ≥ 50–60 Gy. Radiotherapy doses vary in the 
literature, as in our study and range from < 50 to 
70 Gy [7, 9]. 
In our study, the treatment technique evolved 
over time from a two dimensional planning tech-
nique (2DRT) in which an anterior and posterior 
beam arrangement was employed from orthogonal 
imaging with a posterior spinal cord block, through 
3DCRT with the Eclipse treatment planning system 
(TPS) (Varian Medical Systems, Palo Alto, CA), to 
intensity modulated radiation therapy (IMRT) with 
VMAT in 2020 Monaco TPS (Elekta CMS, Mary-
land Heights, MO, USA). 
While Table 4 appears to reflect reduced toxic-
ity for patients treated with 2DRT compared with 
3DCRT and reduced toxicity with 3DCRT com-
pared with VMAT, we noted documentation of 
toxicities improved with time and we believe that 
this, along with the lower total dose of 46 Gy in 29 
bidaily fractions delivered with 2DRT, is the rea-
son for these discrepancies. We provide table 4 to 
highlight the most common toxicities experienced 
during trimodal therapy for anaplastic thyroid 
carcinoma rather than for a comparison between 
techniques.
This study demonstrates that the potential exists 
for survival of at least years following treatment 
for ATC in select patients. One patient remains 
disease-free 42.9 months and another 9.8 months 
following surgical resection. The third patient who 
remains alive recently completed treatment and has 
been well to date. This trend has also been reported 
in several studies, with a minority of patients sur-
viving for several years following the trimodal treat-
ment [6, 8]. The patient who is disease-free at 42.9 
months post-surgery had co-existent differentiated 
thyroid carcinoma which has been reported to be 
associated with improved outcomes [7]. While it is 
interesting to note that survival following diagnosis 
of distant metastases (0.2, 1.4 and 2.5 months) was 
shorter than survival following local recurrence (4 
months), further interpretation is precluded due to 
the small size of the study.
Only one of the seven patients (14.2%) devel-
oped locoregional recurrence. Given the potential 
morbidity associated with local invasion and me-
chanical compression of nearby structures by the 
primary tumour, trimodal therapy may have a role 
in symptom prevention and reduced morbidity 
even for those patients who subsequently develop 
distant metastases [14]. It is essential, therefore, that 
all patients with a diagnosis of ATC are referred to 
specialist centres and are discussed in a multidisci-
plinary team setting.
Despite aggressive multimodal treatment, the 
prognosis of ATC remains grave. The study and 
development of alternative therapeutic strate-
gies is essential in order to improve the quality 
of life and prognosis of affected patients. Immu-
notherapeutic agents, including pembrolizumab 
[15], atezolizumab [16], tyrosine kinase inhibi-
tors such as levatinib [17, 18] and oncolytic virus 
therapy [19, 20] are currently under investigation 
and have demonstrated promising results in pre-
liminary trials. 
The complete pathological response in the pa-
tient who completed neoadjuvant CRT demon-
strates the potential responsiveness of ATC to CRT. 
In the future, molecular diagnosis and targeted 
treatment may replace doxorubicin-based neoad-
juvant CRT in inoperable cases. Several studies 
have investigated the impact of genetic activa-
tions, such as the mutational activation of BRAF 
on potential treatment options. Targeted therapy 
with dabrafenib, a BRAF inhibitor, and trametinib, 
a MEK inhibitor, has been shown to be an effec-
tive treatment approach in BRAF mutated ATC 
[21, 22]. When used in the neoadjuvant setting, 
this regimen has demonstrated a high pathological 
response rate with one case series reporting 100% 
locoregional control rates and overall survival of 
100% and 83% at six months and one year, re-
spectively [23]. Next generation sequencing analy-
sis, where available, can characterise the cancer 
genome, identify targetable mutations, and guide 
systemic treatment decisions [24]. The continuous 
evolution of targeted therapy tailored to molecular 
mutations may significantly change our treatment 
of ATC in the future. 
However, at present, we would recommend sur-
gery as a first line approach in all cases of ATC 
that are considered operable at presentation, with 
neoadjuvant treatment reserved only for cases con-
sidered inoperable. Limitations of the study include 
the retrospective nature, small cohort, and the short 
follow-up for surviving patients. Radiotherapy and 
doxorubicin doses varied between patients. Deci-
sions regarding doses, however, were made indi-
vidually for each patient taking the extent of dis-
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ease, comorbidities and performance status into 
consideration. While inhomogeneities exist in the 
treatment group, this paper reflects outcomes for 
patients treated in clinical practice. Given that most 
recurrences of ATC occur very soon after treatment 
[5], we believe that our findings regarding local 
control are meaningful. 
conclusions
ATC has a poor prognosis with high rates of re-
currence and mortality. In some patients, trimodal 
therapy can be associated with a good outcome, 
with one of our patients remaining disease-free 
more than three years following treatment.
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